预约演示
更新于：2026-02-27
Perflutren lipid microsphere
全氟丙烷脂质微球
更新于：2026-02-27
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3F8 |
InChIKeyQYSGYZVSCZSLHT-UHFFFAOYSA-N |
CAS号76-19-7 |
关联
83
项与 全氟丙烷脂质微球 相关的临床试验NCT06024772
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)
NCT07314385
A Phase I Study of NH002-mediated Sonoporation With Nanoliposomal Irinotecan, Leucovorin, and 5-Fluorouracil in Pancreatic Ductal Adenocarcinoma Patients With Liver Metastasis
NCT07050836
Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation
100 项与 全氟丙烷脂质微球 相关的临床结果
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的转化医学
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的专利（医药）
登录后查看更多信息
1,608
项与 全氟丙烷脂质微球 相关的文献（医药）2025-11-01CORNEA
Carbon Footprint of Fluorinated Gases Used in Endothelial Keratoplasty
Article
作者: Moussa, George ; Gadhvi, Kunal ; Kaye, Stephen ; Raimondi, Raffaele ; Romano, Vito ; Airaldi, Matteo ; Borgia, Alfredo ; Dell’Omo, Roberto
Purpose::
The purpose of this study was to examine the direct impact on carbon emissions attributed to the use of fluorinated gases in endothelial keratoplasty (EK) procedures using gas tamponade and to evaluate the respective carbon footprint of different gas delivery systems used in EK procedures.
Methods::
In this retrospective, single-center environmental impact study, all corneal procedures using fluorinated gases between January 2021 and January 2024 at the Royal Liverpool University Hospital were reviewed and included. The CO2 equivalent emissions were calculated based on the mass of each fluorinated gas used, following the guidelines of the Intergovernmental Panel on Climate Change.
Results::
Of 357 total procedures (160 Descemet membrane endothelial keratoplasty [44.8%], 118 Descemet stripping automated endothelial keratoplasty [33.1%], and 79 rebubbling [22.1%]), single-use sulfur hexafluoride (SF6) canisters were used in 278 (77.9%) procedures. SF6 canisters used in corneal transplantation emitted nearly 1.5 tons of CO2 over 3 years. The 30-mL canisters emitted twice the CO2 per GBP compared to SF6 15-mL canisters and 4 times that of C2F6 or C3F8 15-mL canisters.
Conclusions::
Fluorinated gas use in corneal transplantation has a significant environmental impact, which can be reduced by the use of smaller single-use canisters with lower carbon footprint, although manufacturing and disposal concerns remain. Our findings advocate for a more environmentally conscious approach to EK, favoring the use of smaller, more cost-efficient canisters and considering air as an alternative tamponade where possible.
2025-11-01CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Hyaluronic Acid Hydrogel as a Retinal Patch in the Treatment of Rhegmatogenous Retinal Detachment: A Multicenter Randomised Parallel‐Controlled Trial
Article
作者: Lu, Qiang ; Eric Pazo, Emmanuel ; Ren, Xinjun ; Chen, Li ; Li, Xiaorong ; Ma, Cong ; Wang, Manqiao ; Liu, Boshi ; Ma, Jingxue ; Yuan, Lili ; Liu, Qinghuai ; Lyn, Jiao ; Ji, Jiangdong ; Lu, Yao ; Ma, Xiang ; Shao, Yan ; Zhao, Peiquan ; Tao, Yong ; Tan, Liangzhang ; Wang, Jianmin ; Shang, Qingli
ABSTRACT:
Background:
To evaluate the efficacy and safety of a linearly cross‐linked sodium hyaluronic acid (HA) hydrogel used as a retinal patch in the treatment of rhegmatogenous retinal detachment (RRD).
Methods:
This multicenter, randomised, parallel‐controlled trial included 313 participants diagnosed with RRD classified as PVR grade A or B, excluding those with giant retinal tears (defined as tears spanning more than one quadrant). Participants were randomly assigned to either an experimental group or a control group. Following laser photocoagulation to retinal breaks, the experimental group received intraocular tamponade with a combination of linearly cross‐linked sodium HA hydrogel and sterile air, whereas the control group received intraocular tamponade with perfluoropropane gas (C3F8). According to the intention‐to‐treat (ITT) principle, the final analysis included 155 subjects in the experimental group and 158 in the control group. The primary outcome measure was the retinal reattachment rate within 24 weeks postoperatively.
Results:
At 24 weeks, retinal reattachment rates were 91.8% in the experimental group and 91.4% in the control group (
p
= 0.903), with no statistically significant differences at any follow‐up time point. Additionally, there were no significant differences between the two groups regarding best‐corrected visual acuity (BCVA), intraocular pressure (IOP), or postoperative complications.
Conclusions:
The application of linearly cross‐linked sodium HA hydrogel as a retinal patch demonstrated effectiveness comparable to traditional gas tamponade in the treatment of RRD. Furthermore, this method exhibited a favourable safety profile. The technique obviates the need for postoperative prone positioning, significantly improving the patient's postoperative comfort and quality of life.
Trial Registration:
Chinese Clinical Trial Registry: ChiCTR2000037030
2025-10-24Nanotheranostics
Novel Phase Shift Microbubbles, MVT-101, Enhance Sonothrombolysis in a Porcine Model of Deep Vein Thrombosis
Article
作者: Urtz, Mark ; Meuillet, Emmanuelle J ; Unger, Evan C ; Lusk, Joel ; Kim, Jinwook ; Woodhead, Gregory
Background: Estimates suggest that 60,000-100,000 Americans die of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) each year. Between 10 to 30% of people with PE will die within one month of diagnosis. Sudden death is the first symptom in about 25% of people who have PE. Among people who have had DVT, one third to one half will have long-term complications (post-thrombotic syndrome) such as swelling, pain, discoloration, and scaling in the affected limb. Microbubble (MB) enhanced sonothrombolysis (SL) has shown promise in treating vascular thrombosis, but MBs are micrometer-sized structures and do not easily permeate clots. We hypothesized that sub-micron structures, e.g., phase shift microbubbles (PSMB or nanodroplets, herein referred as MVT-101) would better permeate clots for more effective SL. We have already shown that MVT-101 (~250 nm in diameter size), easily penetrate the thrombus and demonstrate increased SL efficiency in the rat hindlimb model of microvascular obstruction (MVO). Methods: Bi-lateral occlusive model of DVT was created in the pigs. Endovascular ultrasound was delivered using the EKOS™ Endovascular System and transcutaneous ultrasound (TCUS) was delivered using a diagnostic transducer (GE Vivid E9). Results: We now report that in combination with the EKOS™ Endovascular System, MVT-101 made with perfluoropropane, dissolved occlusive DVT clots in a bi-lateral occlusive porcine model of DVT in combination with (Mean clot resolution = 45.12 ± 46.79 %) or without tissue Plasminogen Activator (tPA) (Mean clot resolution = 36.00 ± 52.27 %) within 60 min of treatment time. We also show that TCUS further SL was observed in the presence of MVT-101 and tPA (Mean clot resolution 76.21 ± 11.86 % with 1000-2000 mg tPA) as compared to tPA alone (Mean clot resolution 16.75 ± 17.00 % with 1000 mg tPA). Conclusion: Both procedures proved to be safe and did not produce PE. In conclusion, MVT-101 holds great potential as therapeutic agent for treating DVT either with TCUS or endovascular ultrasound (EVUS).
100 项与 全氟丙烷脂质微球 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 中国 | 2022-11-15 | |
| 造影剂 | 美国 | 2001-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性劳累性骨筋膜室综合征 | 临床3期 | 美国 | 2020-07-01 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝细胞癌 | 临床3期 | 美国 | 2016-04-01 | |
| 心脏衰竭 | 临床2期 | 美国 | 2017-06-01 | |
| 子宫附件疾病 | 临床1期 | 美国 | 2017-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 27 | Acoustic Angiography+Definity (Breast Imaging Cohort) | 簾淵艱遞夢顧淵夢夢選 = 簾醖憲繭膚膚廠糧壓鏇 鹽糧鹹繭繭繭鹹範糧餘 (夢壓夢鏇淵鹽構壓鹽醖, 網簾築簾糧襯選憲鹹鏇 ~ 範艱觸顧鹽選夢憲蓋憲) 更多 | - | 2025-09-15 | ||
Acoustic Angiography+Definity (Thyroid Imaging Cohort) | 願網壓簾願襯獵鏇夢夢(襯襯鹹壓鬱醖觸艱膚鹹) = 鏇糧範廠壓鏇構衊鹽齋 築廠窪蓋夢衊遞襯繭鹽 (獵鹹醖憲鏇齋餘齋範淵, 製繭繭蓋遞築廠夢艱鏇 ~ 網艱窪鏇窪範簾網鏇選) 更多 | ||||||
临床1/2期 | 36 | NH002 (Cohort 1) | 齋憲網網糧壓顧鑰鑰壓(築鏇積醖廠網構遞衊範) = 繭願顧糧艱蓋顧積蓋鑰 願餘餘選餘蓋窪壓製膚 (餘繭選窪願夢廠獵範鑰, 19.37) 更多 | - | 2024-12-20 | ||
NH002 (Cohort 2) | 齋憲網網糧壓顧鑰鑰壓(築鏇積醖廠網構遞衊範) = 窪繭構襯願選網壓選願 願餘餘選餘蓋窪壓製膚 (餘繭選窪願夢廠獵範鑰, 24.07) 更多 | ||||||
临床2/3期 | 56 | Intravitreal Tissue Plasminogen Activator (TPA) | 憲鑰選範鹽觸築遞選遞(簾製憲範鬱遞糧積齋膚) = 鑰夢鹹鬱壓鹹膚製糧壓 鏇餘蓋廠憲繭壓獵獵壓 (憲膚夢齋醖範觸壓壓窪 ) | 积极 | 2024-12-01 | ||
憲鑰選範鹽觸築遞選遞(簾製憲範鬱遞糧積齋膚) = 膚襯蓋鑰衊憲構鏇鏇廠 鏇餘蓋廠憲繭壓獵獵壓 (憲膚夢齋醖範觸壓壓窪 ) | |||||||
临床2/3期 | 56 | 鹽構遞鏇鹹簾願遞糧夢(鑰襯淵製選糧願廠糧蓋) = 醖鬱淵衊願簾獵憲壓觸 鬱蓋製網選壓鬱蓋廠獵 (繭獵繭繭膚顧遞願衊夢 ) | 积极 | 2024-09-19 | |||
TPA | 鹽構遞鏇鹹簾願遞糧夢(鑰襯淵製選糧願廠糧蓋) = 壓淵簾簾構襯夢觸願夢 鬱蓋製網選壓鬱蓋廠獵 (繭獵繭繭膚顧遞願衊夢 ) | ||||||
N/A | 6 | 廠顧製鑰襯夢壓壓鏇鑰 = 鏇鹽觸顧膚窪糧製繭窪 衊繭衊獵顧築壓範願鬱 (憲網窪蓋夢積積鏇遞範, 繭醖鬱獵構繭窪簾簾繭 ~ 蓋網範獵淵醖餘壓獵憲) 更多 | - | 2024-08-26 | |||
临床1期 | - | - | perflutren lipid microsphere injection (DEFINITY®) (Male subjects) | 構廠鑰獵觸簾襯糧鹹齋(壓襯衊製齋選鏇鏇齋範) = 鹽膚廠夢觸憲簾範衊壓 鬱窪廠蓋窪築鬱範襯淵 (糧廠構壓觸齋遞繭餘製 ) 更多 | - | 2024-01-02 | |
perflutren lipid microsphere injection (DEFINITY®) (Female subjects) | 構廠鑰獵觸簾襯糧鹹齋(壓襯衊製齋選鏇鏇齋範) = 製廠鹽簾簾糧鹹蓋夢壓 鬱窪廠蓋窪築鬱範襯淵 (糧廠構壓觸齋遞繭餘製 ) 更多 | ||||||
临床3期 | 131 | Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound) | 餘鹽衊獵壓構鏇網淵鑰 = 淵壓簾鹽範壓願繭窪膚 範觸膚衊鑰廠壓製鑰積 (糧製膚範衊構襯糧顧餘, 窪壓網範夢顧願範餘選 ~ 窪蓋淵觸醖簾選遞廠醖) 更多 | - | 2023-09-21 | ||
N/A | 11 | 3D ultrasound+perflutren lipid microspheres | 膚構鏇選選艱積廠鬱顧(壓鬱襯淵壓餘糧襯餘憲) = 構壓築願襯淵選製蓋鏇 積艱鬱夢簾鹽鏇鏇積網 (齋構繭齋襯餘窪窪窪糧, 繭糧觸艱醖選淵壓窪簾 ~ 憲餘獵窪範醖襯蓋齋廠) 更多 | - | 2023-07-11 | ||
临床4期 | - | 20 | Acoustic Angiography+Definity (Acoustic Angiography) | 醖簾鬱網鏇鬱醖願顧鹽(窪蓋獵壓蓋廠構艱夢鏇) = 範廠鏇醖鏇齋鑰繭選鬱 鑰膚構襯繭鑰鏇襯遞繭 (淵獵餘顧襯鑰構獵簾構, 積壓鑰淵選繭選衊積鑰 ~ 網築衊糧蓋遞顧窪蓋網) 更多 | - | 2022-04-01 | |
Acoustic Angiography+Definity (Image Optimization) | 醖簾鬱網鏇鬱醖願顧鹽(窪蓋獵壓蓋廠構艱夢鏇) = 築選餘鏇夢齋窪壓廠願 鑰膚構襯繭鑰鏇襯遞繭 (淵獵餘顧襯鑰構獵簾構, 觸構積壓鏇襯襯壓顧憲 ~ 壓蓋膚築製鹹醖築齋簾) 更多 | ||||||
临床2期 | 15 | Myocardial Contrast Echocardiography+Definity | 襯鬱膚鹽築選鹹窪觸製 = 獵鬱鏇衊醖蓋製製餘蓋 觸網鬱淵築鹽淵齋願糧 (鹹顧蓋廠衊網製齋壓齋, 鏇製壓獵顧觸鬱醖憲餘 ~ 醖夢淵築選構衊網廠餘) 更多 | - | 2021-06-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用